MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
6.39
+0.39
+6.50%
After Hours: 6.39 0 0.00% 16:02 11/29 EST
OPEN
6.04
PREV CLOSE
6.00
HIGH
6.62
LOW
6.00
VOLUME
1.13M
TURNOVER
0
52 WEEK HIGH
23.18
52 WEEK LOW
5.25
MARKET CAP
480.18M
P/E (TTM)
-4.4295
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TVTX last week (1120-1124)?
Weekly Report · 3d ago
Where Travere Therapeutics Stands With Analysts
Travere therapeutics has an average price target of $16.91 with a high of $30.00 and a low of $7.00. In the last 3 months, 11 analysts have offered 12-month price targets for the company. The company has observed the following analyst ratings in the last quarter.
Benzinga · 11/20 13:00
Weekly Report: what happened at TVTX last week (1113-1117)?
Weekly Report · 11/20 12:14
Citigroup Initiates Coverage On Travere Therapeutics with Neutral Rating, Announces Price Target of $7
Benzinga · 11/20 10:55
Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)
TipRanks · 11/14 12:36
Mirum draws $60 target from Morgan Stanley on liver disease prospects
Morgan stanley launches coverage of mirum pharmaceuticals with an overweight rating and a $60 target. The analyst cites the biotech's leadership in rare liver diseases. Morgan stanley's lead product candidate, livmarli, is approved in the u.s. And eu for rare liver disease.
Seeking Alpha · 11/13 19:38
Weekly Report: what happened at TVTX last week (1106-1110)?
Weekly Report · 11/13 12:05
Maintaining Buy Rating for Travere Therapeutics Amid Mixed Q3 Performance and Revised Filspari Estimates
TipRanks · 11/10 11:24
More
About TVTX
Travere Therapeutics Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and delivering therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products are Thiola and Thiola EC (tiopronin tablets) used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company has received approval of FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin 1 and angiotensin-II) and is a non-immunosuppressive therapy approved for the treatment of this condition. FILSPARI (sparsentan) is a dual endothelin angiotensin receptor antagonist (DEARA). Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN in the United States and Europe.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.